Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System

Not Applicable

Active, not recruiting

• Conditions: Peripheral Artery Disease

• Registration Number: NCT05007925
• Lead Sponsor: Shockwave Medical, Inc.

Brief Summary

To assess the continued safety, effectiveness, and optimal clinical use of the Shockwave Medical Peripheral IVL System for the treatment of calcified, stenotic BTK arteries.

Post-market, prospective , multi-center, single-arm study.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-08-09
• Study First Submitted QC: 2021-08-09
• Study First Posted: 2021-08-17
• Study Start: 2021-11-18
• Primary Completion: 2024-03-25
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-05
• Last Update Posted: 2024-12-10
• Study Completion: 2026-04-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• General Inclusion Criteria

1. Age of subject is ≥ 18.

2. Subject is able and willing to comply with all assessments in the study.

3. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and has signed the approved consent form.

4. Critical limb ischemia (CLI) in the target limb from the distal segment (P3) of the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 4-5; or Rutherford 3 in the target limb from the distal segment (P3) of the popliteal artery to the ankle joint prior to the study procedure.

5. Estimated life expectancy >1 year.

   • Angiographic Inclusion Criteria

6. Up to 2 below-the-knee target lesion(s) in native vessels in one or both limbs.

7. Target lesion reference vessel diameter (RVD) between 2.0 mm and 4.0 mm by investigator visual estimate.

8. Target lesion with ≥70% stenosis by investigator visual estimate.

9. Target lesion length is ≤200 mm by investigator visual estimate. Target lesion can be all or part of the 200 mm treated zone.

10. Distal reconstitution of at least one pedal vessel (<50% stenosis) (desert foot excluded).

11. Evidence of at least moderate calcification at the target lesion site by angiography/IVUS OR non-dilatable lesion indicating presence of calcium. Must meet one of the following:

    1. Angiography requires fluoroscopic evidence of calcification on parallel sides of the vessel and extending > 50% the length of the lesion.
    2. IVUS requires presence of ≥270 degrees of calcium over the course of at least 10mm.
    3. Non-dilatable lesion requires attempted treatment with PTA during the index procedure with residual stenosis > 50% and no serious angiographic complications.

Exclusion Criteria

• General Exclusion Criteria

1. Rutherford Category 0, 1, 2 or 6 (target limb).

2. Osteomyelitis or deep soft tissue infection extending proximal from the metatarsals that cannot be treated with an individual toe ray amputation or transmetatarsal amputation (TMA) .

3. History of endovascular or surgical procedure on the target limb within the last 30 days, or planned within 30 days of the index procedure.

4. Subject in whom antiplatelet or anticoagulant therapy is contraindicated.

5. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.

6. Subject has known allergy to urethane, nylon, or silicone.

7. Myocardial infarction within 30 days prior to enrollment.

8. History of stroke within 60 days prior to enrollment.

9. Subject has acute or chronic renal disease with eGFR <30 ml/min/1.73 m2 (using CKD-EPI formula), unless on renal replacement therapy.

10. Subject is pregnant or nursing.

11. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.

12. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.

13. Covid-19 diagnosis within 90 days.

14. The planned use of cutting/scoring balloons, re-entry or atherectomy devices in target lesions during the index procedure.

15. Planned major amputation (of either leg).

16. Acute limb ischemia.

17. Occlusion of all the inframalleolar outflow arteries/vessels (i.e., desert foot).

18. Subject has an anticipated life span of less than one (1) year.

19. Subject already enrolled into this study.

    • Angiographic Exclusion Criteria

20. Failure to treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries with ≤30% residual stenosis, and no serious angiographic complications (e.g., embolism).

21. Failure to successfully treat significant non-target infra-popliteal lesions prior to treatment of target lesion(s). Successful treatment is defined as obtaining ≤50% residual stenosis with no serious angiographic complications (e.g., embolism ).

22. Failed PTA in target lesion during index procedure with angiographic evidence of serious angiographic complications .

23. Target lesion includes in-stent restenosis.

24. Evidence of aneurysm or thrombus in target vessel.

25. No calcium or mild calcium in the target lesion.

26. Target lesion within native or synthetic vessel grafts.

27. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Procedure Success	At procedure	Procedure Success defined as ≤50% residual stenosis for all treated target lesions without serious angiographic complications (flow-limiting dissection, perforation, distal embolization, or acute vessel closure) as assessed by the angiographic core lab
Major Adverse Limb Events (MALE) + Post-Operative Death (POD)	30 days	Major Adverse Limb Events (MALE) + Post-Operative Death (POD) at 30 days defined as a composite of: * all-cause death; * above-ankle amputation of the index limb; * major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving a BTK artery

Secondary Outcome Measures

Name	Time	Method
Serious angiographic complications	At procedure	Serious angiographic complications (flow-limiting dissection, perforation, distal embolization, or acute vessel closure) as assessed by the angiographic core lab
Clinically Relevant Target Lesion Failure (CR-TLF)	30 days, 6, 12 & 24 months	Clinically Relevant Target Lesion Failure (CR-TLF) at 30 days, 6, 12 \& 24 months defined as a composite of: * CD-TLR; * Ischemia-related major amputation; * Clinically relevant target lesion occlusion
Major Adverse Events (MAE)	30 days	Major Adverse Events (MAE) at 30 days defined as a composite of: * Need for emergency surgical revascularization of target limb; * Unplanned target limb major amputation (above the ankle); * Symptomatic thrombus or distal emboli that require surgical, mechanical, or pharmacologic means to improve flow, and extend hospitalization; * Perforations that require an intervention, including bail-out stenting
Ankle-brachial index (ABI) or toe-brachial index (TBI)	30 days, 6, 12 & 24 months	Ankle-brachial index (ABI) or toe-brachial index (TBI) at 30 days, 6, 12 \& 24 months, reported as change from baseline
Primary Patency	6 and 12 months	Primary Patency at 6 and 12 months defined as the absence of both total occlusion (100% diameter stenosis by DUS) in all of the target lesions in a flow pathway, as well as a Clinically-Driven Target Lesion Revascularization (CD-TLR)
VascuQoL	30 days, 6, 12 & 24 months	Quality of Life (QoL) assessed by VascuQoL questionnaire at 30 days, 6, 12 \& 24 months, reported as change from baseline
Lesion Success	At procedure	Lesion Success defined as final residual stenosis ≤50% in the target lesion without significant angiographic complications as assessed by the angiographic core lab
Rutherford Category	30 days, 6, 12 & 24 months	Rutherford Category at 30 days, 6, 12 \& 24 months, reported as change from baseline

Trial Locations

Locations (43)

UCSF Fresno; 🇺🇸 Fresno, California, United States

Scripps Memorial Hospital; 🇺🇸 La Jolla, California, United States

Cedars-Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Stanford Hospital; 🇺🇸 Palo Alto, California, United States

UC Davis Health; 🇺🇸 Sacramento, California, United States

St. Helena Hospital; 🇺🇸 Saint Helena, California, United States

MedStar Washington Hospital Center; 🇺🇸 Washington, District of Columbia, United States

Tallahassee Memorial Hospital; 🇺🇸 Tallahassee, Florida, United States

Piedmont Heart Institute; 🇺🇸 Atlanta, Georgia, United States

Rush University Medical Center; 🇺🇸 Chicago, Illinois, United States

Scroll for more (33 remaining)